Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease.

Ozer N, Schiffer CA, Haliloglu T.

Biophys J. 2010 Sep 8;99(5):1650-9. doi: 10.1016/j.bpj.2010.06.064.

2.

Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

Nalam MN, Ali A, Altman MD, Reddy GS, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, Rana TM, Schiffer CA.

J Virol. 2010 May;84(10):5368-78. doi: 10.1128/JVI.02531-09. Epub 2010 Mar 17.

3.

Protein promiscuity: drug resistance and native functions--HIV-1 case.

Fernández A, Tawfik DS, Berkhout B, Sanders R, Kloczkowski A, Sen T, Jernigan B.

J Biomol Struct Dyn. 2005 Jun;22(6):615-24.

PMID:
15842167
4.
5.

Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.

Chellappan S, Kairys V, Fernandes MX, Schiffer C, Gilson MK.

Proteins. 2007 Aug 1;68(2):561-7.

PMID:
17474129
6.

Inhibition of HIV-1 protease: the rigidity perspective.

Heal JW, Jimenez-Roldan JE, Wells SA, Freedman RB, Römer RA.

Bioinformatics. 2012 Feb 1;28(3):350-7. doi: 10.1093/bioinformatics/btr683.

PMID:
22291339
7.

A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

Muzammil S, Ross P, Freire E.

Biochemistry. 2003 Jan 28;42(3):631-8.

PMID:
12534275
8.

Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.

Weber IT, Waltman MJ, Mustyakimov M, Blakeley MP, Keen DA, Ghosh AK, Langan P, Kovalevsky AY.

J Med Chem. 2013 Jul 11;56(13):5631-5. doi: 10.1021/jm400684f. Epub 2013 Jun 28.

9.

Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.

Naicker P, Achilonu I, Fanucchi S, Fernandes M, Ibrahim MA, Dirr HW, Soliman ME, Sayed Y.

J Biomol Struct Dyn. 2013 Dec;31(12):1370-80. doi: 10.1080/07391102.2012.736774. Epub 2012 Nov 12.

PMID:
23140382
10.

Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease.

King NM, Prabu-Jeyabalan M, Bandaranayake RM, Nalam MN, Nalivaika EA, Özen A, Haliloğlu T, Yilmaz NK, Schiffer CA.

ACS Chem Biol. 2012 Sep 21;7(9):1536-46. Epub 2012 Jul 2.

11.

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

Kozísek M, Cígler P, Lepsík M, Fanfrlík J, Rezácová P, Brynda J, Pokorná J, Plesek J, Grüner B, Grantz Sasková K, Václavíková J, Král V, Konvalinka J.

J Med Chem. 2008 Aug 14;51(15):4839-43. doi: 10.1021/jm8002334. Epub 2008 Jul 4.

PMID:
18598016
12.

Two solutions for the same problem: multiple binding modes of pyrrolidine-based HIV-1 protease inhibitors.

Blum A, Böttcher J, Dörr S, Heine A, Klebe G, Diederich WE.

J Mol Biol. 2011 Jul 22;410(4):745-55. doi: 10.1016/j.jmb.2011.04.052.

PMID:
21762812
13.

Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design.

Velazquez-Campoy A, Muzammil S, Ohtaka H, Schön A, Vega S, Freire E.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):311-28. Review.

PMID:
14754432
14.

A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.

Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.

Proteins. 2004 May 15;55(3):594-602.

PMID:
15103623
15.

Enamino-oxindole HIV protease inhibitors.

Eissenstat M, Guerassina T, Gulnik S, Afonina E, Silva AM, Ludtke D, Yokoe H, Yu B, Erickson J.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):5078-83. doi: 10.1016/j.bmcl.2012.05.120. Epub 2012 Jun 7.

PMID:
22749283
16.

Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.

Ghosh AK, Takayama J, Kassekert LA, Ella-Menye JR, Yashchuk S, Agniswamy J, Wang YF, Aoki M, Amano M, Weber IT, Mitsuya H.

Bioorg Med Chem Lett. 2015 Nov 1;25(21):4903-9. doi: 10.1016/j.bmcl.2015.05.052. Epub 2015 May 30.

17.

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Lefebvre E, Schiffer CA.

AIDS Rev. 2008 Jul-Sep;10(3):131-42. Review.

18.
19.

The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.

Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA.

J Virol. 2010 Oct;84(19):9995-10003. doi: 10.1128/JVI.00505-10. Epub 2010 Jul 21.

20.

Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.

Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC.

J Virol. 2004 Mar;78(6):3123-32.

Supplemental Content

Support Center